Phaseline

Companies › Genexine

Genexine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Efepoetin Alfa
Erythropoietin receptor agonist
EPORPhase 3Anemia of Chronic Kidney DiseaseJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06466785Efepoetin AlfaPhase 3Anemia of Chronic Kidney DiseaseGenitourinaryJun 2027

Targets

EPOR (1)

Companies with the same targets

Takeda Biocad Incepta Pharmaceuticals

Companies built like this

Innovacell Humacyte TolerogenixX Hansa Biopharma Endo USA Inc., a Keenova Therapeutics Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.